单位：[1]Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, No.2 Yinghua East Street, Chaoyang District, Beijing 100029, China.[2]Department of Pulmonary and Critical Care Medicine, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, China.[3]Department of Respiratory Diseases, Tianjin First Center Hospital, Tianjin 300192, China.[4]Department of Respiratory Diseases, Peking University Shenzhen Hospital, Shenzhen 518035, China.北京大学深圳医院深圳市康宁医院深圳医学信息中心[5]Department of Respiratory Diseases, First Hospital of Shanxi Medical University, Taiyuan 030001, China.[6]Department of Respiratory Diseases, The Fifth People’s Hospital of Shanghai, Fudan University, Shanghai 200240, China.[7]Department of Respiratory Diseases, West China Hospital, Sichuan University, Chengdu 610041, China.四川大学华西医院[8]Department of Respiratory Diseases, Suining Central Hospital, Suining 629000, China.[9]Department of Respiratory Diseases, The First Hospital Affiliated to AMU (Southwest Hospital), Chongqing 400030, China.[10]Department of Respiratory Diseases, Qingdao Municipal Hospital, Qingdao 266000, China.
Background The 12-week, multicentre, observational INITIAL study (NCT02143739) assessed asthma severity in newly diagnosed Chinese patients. Methods Post hoc analysis of medication combinations prescribed per routine clinical practice at baseline, and the impact on control levels evaluated using 2012 vs 2018 Global Initiative for Asthma (GINA) criteria. Results In total, 4491 patients were included in the analysis. At baseline, intermittent, mild, moderate and severe asthma was reported in 3.9, 12.0, 22.6 and 61.6% of patients, respectively. Most patients (90.2%) were prescribed inhaled corticosteroid/long-acting beta(2) agonist (ICS/LABA). ICS/LABA plus >= 1 additional medication(s) was prescribed to 66.7% of patients, with leukotriene receptor antagonist (LTRA, 54.7%) being the most common additional medication. Distribution of ICS/LABA vs ICS/LABA+LTRA was comparable in patients with intermittent (3.2% vs 3.0%), mild (11.5% vs 9.7%), moderate (21.2% vs 19.9%) and severe asthma (64.1% vs 67.4%). Control levels among patients using ICS/LABA+LTRA vs ICS/LABA were comparable using GINA 2012 and lower using GINA 2018 criteria. The proportion of patients using ICS/LABA+LTRA vs ICS/LABA with intermittent, mild, moderate and severe asthma controlled at Week 12 (using GINA 2012) were 78.1% vs 80.0, 86.5% vs 85.8, 78.5% vs 71.3, and 59.6% vs 61.8%, respectively. Using GINA 2018 criteria proportions were 86.8% vs 95.9, 86.1% vs 93.2, 82.1% vs 85.3, and 71.9% vs 77.6%, respectively. Conclusions Asthma control was not improved by adding LTRA to ICS/LABA and may have been unnecessary for some newly diagnosed patients. These findings were irrespective of the GINA criteria (2012 vs 2018) used and baseline severity.
第一作者单位：[1]Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, No.2 Yinghua East Street, Chaoyang District, Beijing 100029, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Jiangtao Lin,Xiuhua Fu,Ping Jiang,et al.Post hoc analysis of initial treatments and control status in the INITIAL study: an observational study of newly diagnosed patients with asthma[J].BMC PULMONARY MEDICINE.2020,20(1):doi:10.1186/s12890-020-1069-2.
APA：
Jiangtao Lin,Xiuhua Fu,Ping Jiang,Weidong Song,Xiaoyun Hu...&Huaping Tang.(2020).Post hoc analysis of initial treatments and control status in the INITIAL study: an observational study of newly diagnosed patients with asthma.BMC PULMONARY MEDICINE,20,(1)
MLA：
Jiangtao Lin,et al."Post hoc analysis of initial treatments and control status in the INITIAL study: an observational study of newly diagnosed patients with asthma".BMC PULMONARY MEDICINE 20..1(2020)
